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ORIGINAL ARTICLE
The immunosuppressive cytokine interleukin-4 increases the
clonogenic potential of prostate stem-like cells by activation of
STAT6 signalling
G Nappo1,2, F Handle3, FR Santer3, RV McNeill4, RI Seed1, AT Collins1, G Morrone2, Z Culig3,7, NJ Maitland1,5,7 and HHH Erb1,6,7
Interleukin-4 plays a critical role in the regulation of immune responses and has been detected at high levels in the tumour
microenvironment of cancer patients, where concentrations correlate with the grade of malignancy. In prostate cancer, interleukin-
4 has been associated with activation of the androgen receptor, increased proliferation and activation of survival pathways such as
Akt and NF-κB. However, its role in therapy resistance has not yet been determined. Here we investigate the inﬂuence of
interleukin-4 on primary epithelial cells from prostate cancer patients. Our data demonstrate an increase in the clonogenic potential
of these cells when cultured in the presence of interleukin-4. In addition, a Phospho-Kinase Array revealed that in contrast to
previously published work, signal transducer and activator of transcription6 (STAT6) is the only signalling molecule activated after
interleukin-4 treatment. Using the STAT6-speciﬁc inhibitor AS1517499 we could conﬁrm the role of STAT6 in increasing colony-
forming frequency. However, clonogenic recovery assays revealed that interleukin-4 does not rescue the effects of either irradiation
or docetaxel treatment. We therefore propose that although the interleukin-4/STAT6 axis does not appear to be involved in therapy
resistance, it does play a crucial role in the colony-forming abilities of the basal cell population in prostate cancer. IL-4 may
therefore contribute to disease relapse by providing a niche that is favourable for the clonogenic growth of prostate cancer
stem cells.
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INTRODUCTION
Prostate cancer (PCa) is one of the most frequent malignancies in
males.1 Treatment is strongly dependent on tumour stage, patient
age, overall patient health and tumour risk assessment.24 The
most commonly used treatment options for PCa are radical
prostatectomy, radiation therapy, multiple endocrine therapies
and chemotherapy with docetaxel. Although most PCa patients
respond initially to androgen deprivation treatment, the cancer
inevitably recurs and progresses to highly aggressive castration-
resistant PCa, for which only palliative therapeutic options exist.3,5
However, the exact mechanism behind the development of
castration-resistant PCa is still unclear. One possible reason for this
progression is that currently used therapies have only been
designed to target androgen receptor-positive luminal cells in
the cancer.5 However, several studies have demonstrated that a
small population of primitive cells with a basal phenotype
(characterized by AR−, CD49f+, CD44+, CKs 5/14+ and p63+
markers) exist within the tumour, and have the capacity to evade
current therapies.68 These rare cells (o1%) have been shown to
possess a higher regenerative potential and express tumour
markers (including AMACR and theTMPRSS2-ERG fusion gene).911
Similar to benign prostate tissue, the basal cells (CD44+/CD49f+)
from malignant areas can further be subgrouped by high
expression of α2β1 integrin complex (CD49b), which results in
a rapid adhesion to collagen.12 The basal compartment can also
be further fractionated into stem cells (SC, CD49bhigh/CD133+), the
highly proliferative transit-amplifying cells (TA, CD49bhigh/CD133−)
and committed basal cells (CB, CD49blow/CD133−).5,10 CB cells
have also been reported in several studies as intermediate
cells, and harbour luminal and basal markers, such as cytokeratins
5, 14 and 18.5,10 Interestingly, SC isolated from malignant areas
(cancer stem cells, CSC) are highly invasive, have a shorter
population doubling time and a distinct messenger RNA (mRNA)
and microRNA proﬁle compared to normal SC, and in addition can
form tumours in mice.10,11,13
Recent clinical studies have demonstrated that inﬂammation is
not only linked to the development of cancer, but is also an
indicator of poor prognosis.8,14 Chronic inﬂammation has been
associated with the production of a variety of cytokines by
inﬂammatory cells, including interleukin (IL)-1, IL-6 and IL-4.15 In
addition to the action on immune cells, cytokines modulate the
different cells types within the tumour microenvironment, and are
able to induce cell transformation.15 For example, increased IL-6
levels have been observed in PCa tissues, and are suggested to
inﬂuence growth and survival pathways.16 IL-6 expression levels in
prostate tissue also (i) correlate with Gleason score and biochemical
recurrence, (ii) inﬂuence tumour initiation and (iii) affect clonogenic
recovery after docetaxel treatment of PCa stem-like cells.1618
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IL-4 is a multifunctional cytokine that plays a critical role in the
regulation of immune responses.19 Cytokine binding to the IL4R
alpha-chain (IL4Rα) subunit results in the activation of mediators
of cell growth, resistance to apoptosis, gene activation and
differentiation.19 The activated signal pathways include AKT,
p44/42 MAPK, NF-κB and the JAK/STAT6 pathways, which
represents the main mediator of IL-4 signalling in immune cells.19
Elevated levels of IL-4 (normally produced by tumour-inﬁltrating
lymphocytes) have been documented in patients with progressive
PCa,2022 and in vitro studies using PCa cell lines have demonstrated
that IL-4 activates NF-κB and androgen receptor in a ligand-
independent manner.23 Treatment of androgen-sensitive LNCaP
cells with IL-4 increased the expression of the co-activators CBP/
p300 and their histone acetyltransferase activity.15,24 Overexpression
of IL-4 resulted in increased proliferation of LNCaP and 22Rv1 cell
lines,25 while IL-4 treatment also induced the proliferation of the
androgen receptor-negative PC3 cells under nutrient-depletion
stress.26
In this study, we investigated the physiological and molecular
effects of the pleiotropic cytokine IL-4 on primary basal prostate
cells, isolated from benign and malignant prostate biopsies. By
simulating an IL-4-containing microenvironment (using IL-4
secreting feeder cells), we determined the effect of IL-4 on
primary basal cell fate, cell mortality, cell invasion, and whether
IL-4 signalling is involved in therapy resistance.
RESULTS
IL4Rα expression in primary prostate epithelial cells
IL-4 acts by binding to a heterodimeric receptor complex,
composed of the IL4Rα and the common gamma chain shared
by several IL receptors.27 To evaluate IL4Rα expression patterns in
benign and malignant prostate tissue, we investigated expression
of IL4Rα in a tissue microarray (TMA) containing both malignant
and adjacent benign areas from 36 PCa patients (Figure 1a). The
TMA showed that IL4Rα is mainly expressed in luminal cells and
signiﬁcantly elevated in cancerous compared to adjacent benign
areas (Figure 1b). The bulk of prostate adenocarcinomas consist of
luminal cancer cells, precluding analysis of the IL4Rα expression
levels in rare cell populations such as the basal cell compartment
in malignant areas.12,28 Due to these technical limitations, the
detection of rare basal cell populations in human tissue by
immunohistochemical methods is highly challenging. To over-
come these limitations, we made use of primary cell cultures from
benign prostate hyperplasia and PCa tissue specimens to amplify
the number of basal epithelial cells. In contrast to the ﬁndings
from the TMA (Figures 1a and b) IL4Rα mRNA (Figure 1c) and
protein levels (Figure 1d) were not signiﬁcantly different between
benign and cancerous CD44+/CD49f+ basal cells, which both
showed comparable expression levels to PC3 cells. Surprisingly,
in view of the TMA data, LNCaP cells expressed only minimal levels
of IL4Rα (Figures 1c and d). To investigate IL4Rα expression in the
individual cell subpopulations, we separated SC, TA and CB
according to their surface markers, as previously described.12,27,28
The functional isolation of SC, TA and CB subpopulations
(based on their clonogenic potential) was conﬁrmed (Suppleme-
ntary Figure 1A), and quantitative real-time PCR analysis of the SC,
TA and CB subpopulations revealed that receptor expression was
signiﬁcantly increased in the cancer (C)SC and cancer transit
amplifying subpopulation within the basal cell population
compared with their benign counterparts (Figure 1e). We were
unable to stratify the clonogenicity of the basal populations or
IL4Rα expression using the expression of another common
prostate (basal) stem cell marker CD49f,8 which marked all basal
cells under these serum-free culture conditions (Supplementary
Figure 1B).8
IL-4 increases the clonogenic potential of primary PCa cells
To simulate an IL-4-containing microenvironment, a human IL-4
complimentary DNA construct was inserted into murine STO cells
by lentiviral transduction. IL-4 expression and bioavailability as a
secreted protein were conﬁrmed by quantitative real-time PCR and
ELISA (Supplementary Figures 2A and B). The newly generated STO
cell lines, STO-GUS (control cell line) and STO-IL-4 (IL-4 secreting cell
line) were used as feeder layers for the primary prostate epithelial
cultures in subsequent experiments in order to investigate the
inﬂuence of IL-4 on clonogenic potential. After 15 days of culture,
benign primary cells co-cultured with STO-IL-4 cells showed a minor
increase in colony forming efﬁciency (CFE), compared to cells co-
cultured with STO-GUS cells (Figure 2a; Supplementary Figure 3A).
In contrast, primary PCa cells showed a signiﬁcantly (~3-fold) higher
clonogenic potential in response to STO-IL-4 (Figure 2b;
Supplementary Figure 3B). Similar effects were seen when PCa
cells were co-cultured with untransduced STO cells in the presence
of 5 ng/ml recombinant IL-4 (Supplementary Figure 3C). To
investigate whether the presence of IL-4 affects the proliferative
ability of primary cells, colony growth was tracked over time.
Surprisingly, there was no signiﬁcant difference between the size of
colonies in STO-GUS or STO-IL-4 co-cultured cells, or between
cancer and benign cells (Figures 2c and d). Similar results were
observed in cell lines and primary cells treated with 5 ng/ml
exogenous IL-4 for 7 days (Supplementary Figures 3DH). Moreover,
[3H] thymidine incorporation assays (Supplementary Figures 3IL)
and MTT assays (Supplementary Figures 3MP) of commonly used
PCa cell lines treated with a concentration range of IL-4 conﬁrmed
that IL-4 is not able to affect cellular proliferation rate or viability,
respectively. To further corroborate whether IL-4 expedites colony
formation, the development of colonies was scored over time. After
6 days, there was a signiﬁcant increase in colony number in primary
PCa cells co-cultured with STO-IL-4 compared to controls (STO-GUS)
(Figure 2e). Thus, IL-4 is able to increase CFE of primary PCa cells but
once colonies have formed, IL-4 is unable to regulate the expansion
of these colonies.
To investigate whether CFE of PCa cells is dependent on the
concentration of IL-4, primary cancer cells were co-cultured with
STO-IL-4/STO-GUS cells at different ratios (Figure 2f). For these
experiments STO-IL-4 cells were diluted with STO-GUS cells to
a maximum ratio of 1:10 000. The IL-4 concentrations of the
supernatants were determined after 2 days by ELISA and showed
a concentration range from 0.004 to 32 ng/ml (Supplementary
Figure 4A). The results demonstrated that the number of colonies
correlated (Supplementary Figures 4B and C; R2= 0.867; P= 0.021)
with the concentration of IL-4 in the supernatant suggesting that
the clonogenic potential of primary PCa cells is increased in
a dose-dependent manner by IL-4. As IL-4 effects on benign cells
were absent, subsequent experiments were performed with
malignant cells only.
IL-4 does not inﬂuence the migration or invasive potential of
primary PCa cells
In order to determine whether IL-4 inﬂuences the chemotaxis of
primary PCa cells, migration (Figure 3a) and invasion assays
(Figure 3b) were performed with Boyden chambers in the presence
of STO-IL-4 and STO-GUS acting as chemoattractants. Media with no
supplements/chemoattractants were used as a negative control and
medium supplemented with 30% fetal calf serum (FCS) was used as
a positive control.13 STO cells in the absence of FCS had a similar
effect on migration and invasion as 30% FCS. However, we were
also unable to see any statistically signiﬁcant effects on migration
and invasion of primary PCa cells when STO-IL-4 was used as a
chemoattractant. Noteworthy, this type of assay does not
discriminate between the different subpopulations of primary PCa
cells. We can therefore not exclude that SC niches do not need to
secrete IL-4 in order to attract SC or CSC.
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IL-4 signalling does not affect the sensitivity of primary PCa cells to
irradiation or docetaxel
Multiple cytokines, such as IL-6, IL-8 and IL-4, have been shown
to be expressed at higher levels after cancer treatment
(for example radiation and chemotherapy (docetaxel)), and
may play a crucial role in resistance mechanisms.15,20,29 In order
to verify whether IL-4 may inﬂuence the recovery potential of
primary cancer cells after irradiation, clonogenic recovery assays
were performed after cells were exposed to increasing doses
of γ-irradiation (2.5, 5, and 10 Gy) in the presence or absence of
IL-4. As expected, γ-irradiation caused a signiﬁcant decrease in
colony numbers (expressed as relative survival fraction)
(Figure 4a). However, there was no signiﬁcant difference in
clonogenic recovery between PCa cells co-cultured with STO-IL-4
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Figure 1. IL4Rα expression in prostate epithelial cells. (a) Immunohistochemical staining for IL4Rα of representative malignant tissue and
adjacent benign tissue cores from a PCa patient. Scale bar= 200 μM. (b) Evaluation of a TMA of malignant tissue and adjacent benign tissue
cores from PCa patients (n= 36) stained for expression of IL4Rα. Data are shown as box and whisker diagrams (10–90%, ***Po0.001, outliers
are shown as dots). (c) IL4Rα mRNA levels in LNCaP (n= 3), PC3 (n= 3), benign (n= 8) and malignant (n= 8) primary prostate cell cultures
normalised to RPLP0 expression. Data are shown as box and whisker diagrams (min to max; *Po0.05). (d) IL4Rα protein levels of LNCaP (n= 3),
PC3 (n= 3), benign (n= 4) and malignant (n= 5) primary prostate cell cultures analysed by ﬂow cytometry. Data are shown as box and whisker
diagrams (min to max; *Po0.05; **Po0.01; ***Po0.001). (e) IL4RαmRNA levels of individual cell subpopulations from benign and malignant
primary prostate cell cultures (n= 6). Data are shown as Box and whisker diagrams (min to max; *Po0.05). CCB, cancer committed basal;
CTA, cancer transit amplifying; NS, not signiﬁcant.
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(inhibitory concentration (IC)50 3.44 ± 1.60 Gy) and the STO-GUS
control (IC50 5.01 ± 0.47 Gy).
To further corroborate whether IL-4 is able to affect the
clonogenic recovery rate in response to a treatment, we repeated
the assays after exposure to docetaxel, a standard of care
chemotherapeutic intervention for castration-resistant PCa.
A signiﬁcant change in primary cell viability after 72 h treatment
with increasing doses of docetaxel was observed (Supplementary
Figure 5A). However, morphological observations (increase in
nuclear size) and cell cycle analysis (G2 arrest) revealed that
docetaxel was already effective at the lowest concentration
(1.25 nM) tested after 24 h treatment (Supplementary Figures
5BE). Subsequently, to investigate whether IL-4 may be involved
in relapse after docetaxel treatment, clonogenic recovery assays
were performed following an initial 48 h treatment with
a concentration range from 1.25 nM to 1.25 μM docetaxel. As
expected, a signiﬁcant decrease in the number of colonies was
observed after docetaxel treatment (Figure 4b). Similar to
irradiation, no signiﬁcant changes in either recovery potential
or the IC50 between docetaxel-treated cells co-cultured with
STO-IL-4 (IC50 1.34 ± 0.24 nM) and co-cultured with STO-GUS
(IC50 1.16 ± 0.06 nM) could be observed (Figure 4b). We concluded
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that IL-4 signalling is not able to decrease the sensitivity of
primary PCa cells in response to irradiation or docetaxel treatment.
IL-4 treatment induces phosphorylation of STAT6 in PCa cells
Next, we assessed which downstream signalling pathways are
activated by IL-4 and may be involved in the increase in
clonogenic potential observed in primary PCa cells. To this end,
a Proteome Proﬁler Human Phospho-Kinase Array was utilised.
Four primary PCa cell cultures from different patients were treated
for either 30 min or 48 h with 48 h-conditioned media from
STO-IL-4 cells. The array revealed that IL-4 treatment triggered
a highly heterogeneous response in primary PCa cells, with only
phosphorylation of signal transducer and activator of transcrip-
tion6 (STAT6) identiﬁed as being signiﬁcantly upregulated
(Po0.05) in all samples and at all time points (Table 1;
Figures 5ac). Activation of STAT6 was validated by Western blot
after treatment with IL-4-containing supernatant from STO-IL-4 for
either 30 min or 48 h (Figure 5d).
Previous immunohistological studies have reported that STAT6
is overexpressed in PCa,30 and assessment of our TMA for STAT6
expression supported these results (Supplementary Figure 6).
However, the data also showed a slight, statistically not signiﬁcant
decrease of both STAT6 mRNA (Figure 5e) and protein (Figure 5f)
levels in cancer-derived primary cells compared to benign cells.
Cancerous primary cells showed similar STAT6 protein expression
to PC3 cells, despite the malignant primary cells demonstrating
higher transcript expression. In contrast, LNCaP cells showed very-
low STAT6 mRNA expression and no detectable protein
(Figures 5eg). In addition, no differences in STAT6 mRNA levels
were observed between the fractionated subpopulations from
cancer or benign cultures (Figure 5h). We concluded that STAT6 is
highly expressed in primary PCa cells, albeit at lower levels than in
benign cells, and can readily be activated by IL-4.
Inhibition of phosphoSTAT6 reverses the IL-4-mediated increase in
clonogenic potential
In order to investigate whether direct inhibition of STAT6
signalling can antagonize the effects of IL-4 on the clonogenic
potential of primary PCa cells, a selective STAT6 inhibitor
(AS1517499) was used at varying concentrations.31 After toxicity
testing in primary cells (Figure 6a), two concentrations of the
inhibitor (100 and 300 nM) were selected for further use, and their
efﬁcacy was veriﬁed by Western blot analysis for STAT6
phosphorylation following IL-4 exposure. While the inhibitor had
no observable effect on cell viability (Figure 6a) and total STAT6
protein expression (Figures 6b and d), the levels of phosphory-
lated STAT6 decreased to 60 and 20% of initial expression levels
following treatment with 100 and 300 nM AS1517499 respectively
(Figures 6b and c).
As shown in Figure 2b, IL-4 increased the clonogenic potential
of primary cancer cells. When PCa cells were co-cultured with
STO-IL-4 in the presence of 100 nM of AS1517499, this increase in
clonogenic potential was found to be signiﬁcantly inhibited
(Po0.05) (Figure 6e). Furthermore, the higher dose of AS1517499
(300 nM) showed an almost complete reversion of IL-4-increased
clonogenic potential, to levels comparable to control (STO-GUS).
Although 300 nM AS1517499 had a minor effect on clonogenic
potential of the STO-GUS-co-cultured PCa cells, we concluded that
the increase of the clonogenic potential of primary PCa cells in
response to IL-4 is indeed mediated by STAT6 activation.
DISCUSSION
The role of important pro-inﬂammatory cytokines such as IL-1 and
IL-6 in carcinogenesis has been extensively investigated.15,32 In
contrast, less is known about the effects of anti-inﬂammatory
cytokines such as IL-4 on PCa cells. IL-4 is a pleiotropic cytokine
produced by a subset of CD4+ T cells in response to receptor-
mediated activation events. It induces a variety of responses in
hematopoietic tissues, signalling mainly through the IL4Rα
subunit, which is present in many tissue types including
hematopoietic, endothelial, epithelial, muscle, ﬁbroblast, hepato-
cyte and brain.3335 Using a TMA, we were able to demonstrate
that IL4Rα is signiﬁcantly overexpressed in luminal PCa cells
compared to cells from benign areas of the human prostate.
Similar results have been observed in PCa xenograft models
where IL4Rα is overexpressed in both androgen-dependent
and -independent tumours.36 These results added PCa to the
group of solid human tumours where IL4Rα is highly expressed,
similar to breast, ovarian and colon cancers.37,38 Interestingly, we
found no signiﬁcant difference in IL4Rα expression between
benign and malignant primary basal prostate cells. However,
fractionation of these rare cell populations revealed that stem-like
cells isolated from cancers have signiﬁcantly higher expression
levels of IL4Rα, suggesting a potential tumourigenic role for
IL-4/IL4Rα in PCa CSCs. Previously, IL-4/IL4Rα signalling activation
was shown to promote clonogenic potential and metastatic
colonisation in stem-like cells from human colon and mammary
cancers.3840 Similar to these ﬁndings, we showed that IL-4
signiﬁcantly increased the clonogenic potential of PCa
primary cells.
Former studies have demonstrated that IL-4 can induce NF-kB
activation through activation of PI3K/AKT in PCa cell lines.23 In
contrast, we found that IL-4 treatment induced only STAT6
phosphorylation in all the patient-derived cell cultures analysed
(despite high heterogeneity between samples). This is supported
by the ﬁndings of Ni et al.,41 who also showed signiﬁcant levels of
activated STAT6 in primary prostate tissues.
Here we describe a new role for IL-4-activated STAT6 in
the regulation of clonogenic potential of primary PCa cells.
Figure 2. IL-4 increases clonogenic potential of primary PCa cells. (a) Clonogenic assays of benign primary prostate cells (n= 4) co-cultured
with STO-GUS or STO-IL-4 feeder cells. The number of colonies (⩾32 cells) was scored 15 days after plating. The results are expressed as fold
change in the number of colonies and are normalised to the STO-GUS control. A representative crystal violet staining is shown at day 15. Data
are shown as mean± s.d. (*Po0.05). (b) Clonogenic assays of malignant primary prostate cells (n= 4) co-cultured with STO-GUS or STO-IL-4
feeder cells. The number of colonies (432 cells) was scored 15 days after plating. The results are expressed as fold change in the number of
colonies and are normalised to the STO-GUS control. A representative crystal violet staining is shown at day 15. Data are shown as mean± s.d.
(*Po0.05). (c) Average colony growth of benign primary prostate cells (n= 3) co-cultured with STO-GUS or STO-IL-4 feeder cells. Cell numbers
from two colonies from each condition were counted at day 8 and 15, and the increase in cell number of one colony expressed as fold change.
Data are shown as mean± s.d. (d) Average colony growth of malignant primary prostate cells (n= 3) co-cultured with STO-GUS or STO-IL-4
feeder cells. Cell numbers from two colonies from each well were counted at day 8 and 15 and the colony growth expressed as fold change.
Data are shown as mean± s.d. (e) Time course of colony formation (⩾32 cells) in primary PCa cell cultures (n= 3) co-cultured with STO-IL-4 or
STO-GUS for 8 days. The results are expressed as total number of colonies. Data are shown as mean± s.e.m. (*Po0.05). (f) Clonogenic assay of
primary PCa cells (n= 3) co-cultured with a combination of STO-GUS and STO-IL-4 feeder cells in different ratios (1:1–1:10 000). The number of
colonies (⩾32 cells) was scored 15 days after plating. The results are expressed as total number of colonies. Data are shown as mean± s.e.m.
(*Po0.05). NS, not signiﬁcant.
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Figure 4. IL-4 does not inﬂuence the recovery potential of primary PCa after irradiation or docetaxel treatment. (a) Clonogenic recovery assay
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(⩾32 cells) was scored 10 days after plating. The results are expressed as % survival decrease in the number of colonies and normalised to no
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co-cultured with STO-GUS or STO-IL-4 feeder cells after 48 h treatment with different doses of docetaxel (0, 1.25, 2.5, 5, 10, 100 and 1250 nM).
The number of colonies (432 cells) was scored 10 days after plating. The results are expressed as % survival decrease in the number of
colonies and normalised to no treatment (0 nM) control (n= 3). IC50 was calculated with GraphPad Prism from these results. IC, inhibitory
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Figure 3. IL-4 does not inﬂuence the migration or invasion potential of primary PCa cells. (a) Fold change in migration of primary cancer cells
after 24 and 48 h incubation compared to controls (n= 4). Keratinocyte-serum free medium (KSFM) without added supplements served as a
negative control for migration (nCTRL 0% FCS). KSFM supplemented with 30% FCS served as positive control (pCTRL 30% FCS; *Po0.05;
**Po0.01; ***Po0.001). (b) Fold change in invasion through matrigel of primary PCa cells after 24 and 48 h incubation compared to controls
(n= 4). KSFM without added supplements served as a negative control for invasion (nCTRL 0% FCS). KSFM supplemented with 30% FCS served
as positive control (pCTRL 30% FCS; *Po0.05; **Po0.01; ***Po0.001). nCTRL, negative Control, pCTRL, positive Control.
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Previous studies from our laboratory have revealed that only
the progenitor subpopulations within primary benign and
malignant cell cultures hold the ability to form colonies
from single cells.12,13,42 This observation, combined with our
results, leads to the hypothesis that IL-4 directly inﬂuences
the CSC population by providing a micro-environmental stimulus
to exit quiescence and initiate the formation of new colonies
from a single cell. This adaptation to the IL-4-producing tumour
microenvironment may play a critical role in the promotion
of novel tumour-initiating foci, and possibly tumour initiation
at distant sites. This hypothesis is supported by previous
ﬁndings, which have demonstrated that (i) knockdown of STAT6
Table 1. Evaluation of the Human Phospho-Kinase Antibody Array after treatment of primary PCa cells with IL-4
Abbreviations: Green, downregulation (n= 4 PCa); IL-4, interleukin-4; PCa, prostate cancer; Red, upregulation; Red rectangle, pSTAT6. X-fold change in
phosphorylation status in primary PCa cells after treatment for 30 min 48 h with conditioned media from STO-IL-4. The results of the Human Phospho-Kinase
Antibody Array were evaluated from densitometry analysis of the spotted membrane normalised to the untreated control (STO-GUS-conditioned media).
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expression can inhibit tumour metastasis in PCa, (ii) STAT6−/− mice
are resistant to metastatic disease and (iii) STAT6 phosphorylation
promotes metastatic potential in colon cancer cells.4345 However,
epithelial to mesenchymal transition has also been linked to
increased clonogenicity, and may play a role in the observed
results.46
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In vitro and in vivo studies with the STAT6 inhibitor Leﬂunomide
have reported reduced growth and promotion of apoptosis in
PCa.47 However, Leﬂunomide is known to have non-speciﬁc
effects and can alter targets other than STAT6.30,48,49 Recently,
Nagashima et al.49 synthesized the potent and selective STAT6
inhibitor AS1517499, which has been utilised in this study.
However, AS1517499 did not reduce proliferation as has been
previously reported for Leﬂunomide. Despite this, we showed that
AS1517499 was able to prevent the IL-4-activated STAT6-mediated
increase of the clonogenic potential of primary PCa cells.
Moreover, at a dose of 300 nM, AS1517499 decreased the
clonogenic potential of primary basal PCa cells. Even though
dose-dependent non-speciﬁc effects of AS1517499 cannot be
excluded, it is more likely that the reduced clonogenic potential
observed is due to the inhibition of basal STAT6 activation, which
has been reported previously.41 These results support the hypo-
thetical novel role of STAT6 in the regulation of the clonogenic
potential of PCa.
Several markers have been identiﬁed in order to isolate the highly
tumourigenic CSC from PCa cell lines, as well as primary PCa cells.50
However, these studies differ in both detection methods and the
cell culture conditions for the CSC population, which has been
shown to be highly adaptive to the microenvironment.51 The model
used here was ﬁrst introduced by Collins and colleagues in 1998,
and the laboratory of Maitland and Collins has since then
demonstrated the reliability of this model in several publications.7
Others have recently published similar data on primary prostate
cells, using the basal cell marker CD49f. In contrast to Smith
and colleagues,8 our data showed that all subpopulations isolated
from our primary cells expressed the same levels of CD49f, in
agreement with Taylor et al.7,9 and Collins et al.12 who also demon-
strated CD49f expression on all the cell subpopulations previously
described by Collins and Maitland.12,13,28 This implies that, despite
the use of different basal cell markers, both groups are ultimately
describing the same populations of prostate epithelial cells.
Cytokines play an important role in the development of therapy
resistance.52,53 Current therapies such as radiation and docetaxel
can trigger an inﬂammatory response, and an increase in cytokine
levels of IL-6, IL-8 and IL-4 have all been reported.15,20,29,54,55
In vitro studies demonstrated that, in cell lines, IL-4 enhances the
DNA repair activity triggered by radiation therapy.56 In this study,
we observed that IL-4 had no inﬂuence on clonogenic recovery of
primary PCa cells following irradiation. Similarly, IL-4 also
demonstrated no inﬂuence on the clonogenic recovery potential
of primary PCa cells following docetaxel treatment. We therefore
conclude that IL-4 does not have a direct inﬂuence on therapy
resistance in PCa.
Here we demonstrate for the ﬁrst time that activation of STAT6
by IL-4 from the local microenvironment results in a signiﬁcant
increase in the colony-forming ability of primary PCa cells. This
ﬁnding describes a novel role of the IL-4/IL4Rα/STAT6 axis in the
highly tumourigenic progenitor population of PCa. However, the
speciﬁc role of STAT6 in rare CSCs has to be clariﬁed in further
studies, in order to investigate STAT6 as a potential novel
therapeutic target. We have also further demonstrated the
complexity of PCa tumour initiation and progression, which
highlights the importance of targeting not only the epithelial cell
populations but also the tumour microenvironment.
MATERIALS AND METHODS
Culture of cell lines and primary prostate cells
The PCa cell lines LNCaP, PC3 and Du145 were obtained from the
American Type Culture Collection (Rockville, MD, USA), cultured, and
authenticated as previously described.57 The LNCaP sub cell line LNCaP
IL-6+ was derived after long-term treatment with IL-6.58 293FT cells were
cultured as described by Invitrogen (Life Technologies Ltd, Paisley, UK).
Benign and cancerous primary prostate cells were cultured as described
previously.6,13,28 Tissues were obtained with patients' consent and full ethical
approval (Yorkshire and Humber NHS Research Ethics OfﬁceNRES number
07/H1304/121) from patients. Stem cell populations (SC, CD49bhigh/CD133+),
transit-amplifying populations (TA, CD49bhigh/CD133−), and committed basal
populations (CB, CD44+/CD49blow/CD133−) were obtained via cell fractiona-
tion using the protocol previously published by Richardson et al.28 Patient
donor details are listed in Supplementary Table 1.
Live cell count
Collected cells were stained with Trypan Blue (Sigma-Aldrich Company Ltd,
Gillingham, UK) and counted using a Neubauers haemocytometer.
Unstained cells were seeded for subsequent experiments.
Irradiation of cells
Cells were irradiated using an RS2000 X-Ray Biological Irradiator, contain-
ing a Comet MXR-165 X-Ray Source (Rad-Source Technologies Inc.,
Suwanee, GA, USA). A dose of 2.5, 5, 10, or 60 Gy was administered with
a dose rate of 0.02 or 0.08 Gy/ s.
STAT6 inhibitor and docetaxel treatment of cells
STAT6 inhibitor (AS1517499, Axon Medchem, Groningen, the Netherlands)
and docetaxel (Sigma-Aldrich Company Ltd) were dissolved in dimethyl
sulfoxide (DMSO, Sigma-Aldrich Company Ltd). For the STAT6 inhibitor
experiments, doses of 10, 30, 100 and 300 nM were used. For docetaxel
experiments, doses of 1.25, 2.5 , 5 , 10 , 100 and 1250 nM were used.
Cloning strategy of pGLTR-IL-4-PURO and pGLTR-GUS-PURO
For cloning of human IL-4 complimentary DNA into the lentiviral vector
pGLTR-X-PURO, the Invitrogen Gateway Recombination Cloning Technol-
ogy (Life Technologies Ltd) was used. pGLTR-X-PURO was kindly provided
by Dr Stephan Geley.59 IL-4 was re-cloned from pcD-human-IL-4(clone 125)
(ATCC, Rockville, MD, USA) using a pair of speciﬁc primers (5-CAAAA
AAGCAGGCTCCATGGGTCTCACCTCCCAAC-3 and 5-CAAGAAAGCTGGGTC
TCAGCTCGAACACTTTGAATATTTC-3), which incorporated speciﬁc over-
hangs for the gateway reaction into the pDONOR221. The pDONOR221-
Escherichia coli-β-glucuronidase (GUS) was used for the control vector
pGLTR-GUS-PURO and was provided by Invitrogen (Life Technologies Ltd).
Figure 5. IL-4 treatment induces phosphorylation of STAT6 in Pca. (a) Representative membranes from the Human Phospho-Kinase Antibody
Array. Samples were treated with 48 h-conditioned media from either STO-GUS controls (ﬁrst lane) or STO-IL-4, for either 30 min (second lane)
or 48 h (third lane). (b) Highlighted pSTAT6 dots on the representative membranes from the Human Phospho-Kinase Antibody Array. (c) Fold
change of pSTAT6 after 30 min and 48 h of IL-4 exposure in the Human Phospho-Kinase Antibody Array compared to the untreated control
(n= 4 PCa). Data are shown as mean± s.d. (*Po0.05 **Po0.01). A two-fold change was chosen as the threshold for upregulation (black line).
(d) Validation for pSTAT6 by Western blot analysis of primary PCa cells treated with conditioned media from STO-GUS or STO-IL-4 for 30 min or
48 h (n= 1). (e) mRNA levels of STAT6 in LNCaP (n= 3) and PC3 (n= 3) cell lines, and benign (n= 8) and malignant (n= 8) primary prostate cell
cultures. Data are shown as Box and whisker diagrams (min to max; *Po0.05). (f) Representative Western blot for STAT6 from primary prostate
benign cells (n= 3), primary PCa cells (n= 3), PC3 (n= 1) and LNCaP (n= 1) cell lines. PC3 cells were used as a positive control and LNCaP cells
as a negative control. (g) Protein levels of STAT6 analysed in primary prostate benign (n= 3) and cancer cells (n= 3) from the representative
Western blot (Figure 5f). PC3 cells were used as a positive control and LNCaP cells as a negative control. Data are shown as Box and whisker
diagrams (min to max; * Po0.05). (h) mRNA levels of STAT6 in individual cell subpopulations from benign and malignant prostate biopsies
(n= 4). Data are shown as Box and whisker diagrams (min to max). CCB, cancer committed basal; CTA, cancer transit amplifying;
NS, not signiﬁcant; Red rectangle, STAT6.
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Lentivirus production and generation of stable cell lines
For production of lentiviral particles, 293FT cells were transfected with
psPAX2, pVSV-G and the corresponding pGLTR-X-PURO expression vector
using the calcium phosphate transfection method.60 psPAX2 was a gift
from Didier Trono (Addgene plasmid # 12260) and pVSV-G was a gift from
Robert Weinberg (Addgene plasmid # 8454).61 Viral supernatants were
harvested 48 h after transfection and passed through a 0.45 μm ﬁlter.
STO cells were incubated for 8 h with the virus in the presence of
2 μg/ml polybrene and subsequently selected with 5 μg/ml puromycin
(Sigma-Aldrich Company Ltd).
[3H] Thymidine incorporation assay and MTT Assay
PC3, Du145 and LNCaP IL-6+ cell lines were seeded at a density of
2 × 103 cells per well and LNCaP cells at 10 × 103 cells per well in triplicate
onto 96-well plates. On the following day, cells were treated with different
concentrations of IL-4 (0, 0.1, 1; 5, 10 ng/ml, Sigma-Aldrich Company Ltd)
and were incubated for 96 h.
To measure DNA synthesis, [3H] labelled thymidine (1 μCi per well)
was added to the wells 12 h before harvesting. The DNA was harvested
on UniFilter 96-well ﬁlter plates (Perkin-Elmer, Vienna, Austria) and
50 μl Scintillation ﬂuid was added. The radioactivity was quantiﬁed
using a Chameleon 5025 liquid scintillation counter (HVD Life Sciences,
Vienna, Austria).
For the MTT Assay the EZ4U Proliferation Assay (Biomedica, Vienna,
Austria) was used and performed following the manufacturers protocol.
Western blot analysis
For Western blot analysis cells were washed with Phosphate-buffered
saline and lysed in Radioimmunoprecipitation assay buffer supplemented
with complete Mini EDTA-free protease inhibitor tablets (Roche, Welwyn
Garden City, UK) and the phosphatase inhibitor cocktail PhosSTOP (Roche).
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Figure 6. Inhibition of phosphoSTAT6 reverses the IL-mediated effects on clonogenic potential. (a) Cell viability of primary PCa cells treated
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phosphorylated and total STAT6 in primary PCa cells exposed to two different (100, 300 nm) doses of AS1517499 combined with STO-IL-4
supernatant for 30 min. (c) Densitometry analysis of pSTAT6 expression in AS1517499/IL-4-treated primary PCa cells compared to untreated
controls (n= 3; *Po0.05 **Po0.01). (d) Densitometry analysis of total STAT6 protein expression in AS1517499/IL-4 treated primary PCa cells
compared to untreated controls (n= 3). (e) Fold change in the number of colonies in primary benign and cancer prostate cells after 15 days of
culture with two doses of AS1517499 (n= 3 benign, n= 3 cancer). (*Po0.05; **Po0.01; ***Po0.001). NS, not signiﬁcant.
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Protein quantiﬁcation and Western blot was performed as described
earlier.62 Antibodies used are listed in Supplementary Table 2. For the
Western blot experiments STO-free cultures were used and treated with
48 h-conditioned media from STO-GUS or STO-IL-4.
Flow cytometry
Flow cytometry for IL4Rα (CD124) was performed as described before by
Kroon et al.18 Antibodies used are listed in Supplementary Table 2.
All experiments were performed in at least three independent biological
replicates unless otherwise speciﬁed.
Clonogenic and clonogenic recovery assays
The clonogenic potential and clonogenic recovery assays were performed
as previously described.63 About 200 cells were plated from semi-conﬂuent
primary prostate cells onto 6-well collagen I-coated plates (BD Biocoat;
BD Biosciences, San Jose, CA, USA) in the presence of irradiated STO cells.
Colonies were counted after 15 days and recorded if they contained more
than 32 cells (ﬁve population doublings).
Cell migration and invasion assays
Cell migration and invasion assays were performed as previously
described.64 All experiments were performed in at least three independent
biological replicates unless otherwise speciﬁed.
Quantitative real-time PCR for mRNA
Total RNA was extracted from cells using Qiagen RNeasy Mini Kit (Qiagen,
Manchester, UK) according to the manufacturer's protocol. RNA was
reverse transcribed using random hexamers (Life Technologies Ltd) and
the Reverse Transcriptase Kit SuperScript III (Life Technologies Ltd).
Quantitative real-time PCR was conducted using TaqMan gene
expression assays (Life Technologies Ltd) and the iTaq Universal Super-
mixes (Bio-Rad Laboratories Ltd, Hertfordshire, UK), according to the
manufacturer's protocol.
Proteome proﬁler human Phospho-Kinase Array
For the Proteome Proﬁler Human Phospho-Kinase Array (R&D, Abingdon,
UK) 1 × 106 primary PCa cells were seeded in a collagen I-coated
10 cm-well plate and treated with 48 h-conditioned media from STO-IL-4
or STO-GUS for 30 min or 48 h. The array was performed according to the
manufacturers manual and developed in a GeneGnome XRQ imaging
system (Syngene, Cambridge, UK).
Tissue microarray and immunohistochemistry
The construction of the TMA for IL4Rα was performed as previously
described.57 Georg Schäfer (Institute of Pathology, Medical University
Innsbruck, Austria) evaluated the TMA by using the semiquantitative
scoring system quickscore by multiplication of the proportion of positive
cells and the average staining intensity.65
Statistical analysis
Prism 6 (GraphPad Software, La Jolla, CA, USA) was used for statistical
analyses and the evaluation of the IC50. Gaussian distribution was
determined using KolmogorovSmirnov test. MannWhitney U or
Students t-test (two-sided) were used to determine whether two sets of
data were signiﬁcantly different from each other. For correlation analysis
(Pearsons method) SPSS (IBM United Kingdom Ltd, Hampshire, UK) was
used. Data are presented as mean± s.d. or mean± s.e.m. unless otherwise
speciﬁed. Mean± s.d. was used to describe the distribution of the sample
values in an experiment and s.e.m was used to estimate how variable the
means were in multiple repeated experiments.66 P-values of o0.05 were
considered signiﬁcant. All differences highlighted by asterisks were statisti-
cally signiﬁcant as encoded in ﬁgure legends (*Po0.05; **Po0.01;
***Po0.001). All experiments were performed in at least three indepen-
dent biological replicates unless otherwise speciﬁed.
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